Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.

Mäki-Petäjä KM., McGeoch A., Yang LL., Hubsch A., McEniery CM., Meyer PAR., Mir F., Gajendragadkar P., Ramenatte N., Anandappa G., Santos Franco S., Bond SJ., Schönlieb C-B., Boink Y., Brune C., Wilkinson IB., Jodrell DI., Cheriyan J.

[Figure: see text].

DOI

10.1161/HYPERTENSIONAHA.120.16454

Type

Journal article

Journal

Hypertension

Publication Date

05/05/2021

Volume

77

Pages

1591 - 1599

Keywords

acetylcholine, cardiovascular disease, hypertension, microvascular rarefaction, pazopanib, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Cardiac Output, Endothelium, Vascular, Female, Hemodynamics, Humans, Hypertension, Indazoles, Male, Middle Aged, Neoplasms, Pyrimidines, Receptors, Vascular Endothelial Growth Factor, Sulfonamides, Vascular Resistance, Vascular Stiffness

Permalink Original publication